> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Gazya
- URL: https://www.fdaweb.com/review-period-set-for-gazya/
- Published: 2016-04-12T12:00:00.000Z
- Updated: 2026-09-14T20:54:09.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135339

*Federal Register* Notice: FDA has determined the regulatory review period for Genentech’s Gazya is 1,698 for extending a patent which claims the human biological product. Gazyva is indicated, in addition with chlorambucil, for treating patients with previously untreated chronic lymphocytic leukemia. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-04-12/pdf/2016-08338.pdf?ref=fdaweb.com)